- Cancer Research UK recruits first patients in trial to improve the early detection and diagnosis of different cancer types
- Study will use Owlstone Medical’s Breath Biopsy platform to identify breath biomarkers to detect and differentiate early-stage disease
- Study will recruit 1,500 patients at Addenbrooke’s Hospital, Cambridge
Cambridge, UK, January 3rd 2019: Owlstone Medical (or the “Company”), a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Cancer Research UK, today announces the clinical launch of the PAN Cancer trial for Early Detection of Cancer in Breath1, with the first patients now being recruited for the 1,500 patient study.
As previously announced on initiation of the collaboration, researchers in the trial are using Owlstone Medical’s2 Breath Biopsy® platform to collect samples, including healthy individuals as trial controls, to analyze volatile organic compounds (VOCs) in the breath. The trial aims to identify VOCs that can be used as breath-based biomarkers to detect and differentiate different cancer types, thereby improving early detection.
This approach holds great promise as cancer cells display altered metabolism even at the very earliest stage of disease, affecting the pattern of the VOCs exhaled. By identifying the changing pattern of VOCs early, Owlstone Medical’s Breath Biopsy technology could detect cancer at the earliest stage of disease, when treatments are more effective and more lives can be saved.
The trial is recruiting 1,500 patients at Addenbrooke’s Hospital in Cambridge who have been referred from their GP with these specific types of suspected cancer. Prior to other diagnostic tests, breath samples will be collected using Owlstone Medical’s ReCIVA® Breath Sampler and processed in Owlstone Medical’s Breath Biopsy laboratory in Cambridge, UK.
The clinical trial has initiated in patients with suspected oesophageal and stomach cancers and will expand to prostate, kidney, bladder, liver and pancreatic cancers in the coming months. Research is anticipated to run through 2021, and if the technology proves to accurately identify cancer the team hope that Breath Biopsy could in the future be used routinely in GP practices to determine whether to refer patients for further diagnostic tests.
Professor Rebecca Fitzgerald, lead trial investigator at the Cancer Research UK Cambridge Centre, said: “We urgently need to develop new tools, like this breath test, which could help to detect and diagnose cancer earlier, giving patients the best chance of surviving their disease. Through this clinical trial we hope to find signatures in breath needed to detect cancers earlier – it’s the crucial next step in developing this technology. Owlstone Medical’s Breath Biopsy technology is the first to test across multiple cancer types, potentially paving the way for a universal breath test.”
Billy Boyle, co-founder and CEO at Owlstone Medical, said: “There is increasing potential for breath-based tests to aid diagnosis, sitting alongside blood and urine tests in an effort to help doctors detect and treat disease. The concept of providing a whole-body snapshot in a completely non-invasive way is very powerful and could reduce harm by sparing patients from more invasive tests that they don’t need."
“Our technology has proven to be extremely effective at detecting VOCs in the breath, and we are proud to be working with Cancer Research UK as we look to apply it towards the incredibly important area of detecting early-stage disease in a range of cancers in patients.”
Almost half of cancers are diagnosed at a late stage in England3. This highlights the importance of early detection, particularly for diseases like oesophageal cancer where only 12% of oesophageal cancer patients survive their disease for 10 years or more. For example, Rebecca Coldrick, 54 from Cambridge, was diagnosed in her early 30s with Barrett’s oesophagus, a condition where the cells lining the oesophagus are abnormal – often caused by acid reflux. Out of 100 people with Barrett’s oesophagus in the UK, up to 13 could go on to develop oesophageal adenocarcinoma4.
Rebecca Coldrick said: “About 20 years ago I developed acid reflux, and I began to live on Gaviscon and other indigestion remedies. I went to the doctors and shortly after I was diagnosed with Barrett’s. Every two years I have an endoscopy to monitor my condition.”
Dr David Crosby, head of early detection research at Cancer Research UK, said: “Technologies such as this breath test have the potential to revolutionize the way we detect and diagnose cancer in the future. Early detection research has faced an historic lack of funding and industry interest, and this work is a shining example of Cancer Research UK’s commitment to reverse that trend and drive vital progress in shifting cancer diagnosis towards earlier stages.”
Recognising the importance of early detection in improving cancer survival, Cancer Research UK has made research into this area one of its top priorities and will invest more than £20 million a year in early detection research by 2019.
To find out more about Owlstone Medical’s Breath Biopsy® platform, visit: https://www.owlstonemedical.com/science-technology/breath-biopsy/
2. While Owlstone will be funding the trial directly, none of this would be possible without the support and infrastructure provided by Cancer Research UK. The PAN Cancer trial is being conducted in collaboration with a team of leading cancer researchers at the Cancer Research UK Cambridge Centre, the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. The Chief Investigator is Professor Rebecca Fitzgerald, who is co-lead of the Cancer Research UK Cambridge Centre Early Detection Programme, Professor of Cancer Prevention at the MRC Cancer Unit, and an Honorary Consultant in Gastroenterology and General Medicine at Addenbrooke's Hospital, Cambridge.
3. For all cancers (excluding non-melanoma skin cancer) diagnosed at a late stage (3 or 4) of those with a known stage at diagnosis in England (2016). Source: http://www.ncin.org.uk/publications/survival_by_stage
4. Gatenby P, Caygill C, Wall C, et al. Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus. World J Gastroenterol 2014; 20(28):9611-7.
Notes to Editors
Breath Biopsy® ReCIVA Breath Sampler
For a high-resolution image please contact firstname.lastname@example.org
For Owlstone Medical
Sarah Jeffery, Zyme Communications
+44 (0)7771 730 919
For Cancer Research UK
Angharad Kolator Baldwin
+44 (0)20 3469 8456 / +44 (0)7050 264 059 (out of hours)
What is Breath Biopsy®?
Breath Biopsy represents an entirely new way to measure the chemical makeup of breath by measuring volatile organic compounds (VOCs), gaseous molecules that can be sampled quickly and non-invasively from breath, and enabling whole-body sampling. These compounds are produced as the end product of metabolic processes within the body, meaning that underlying changes in metabolic activity can produce particular patterns of VOCs characteristic of specific diseases.
VOCs originating from all parts of the body are captured in breath, making Breath Biopsy applicable to a wide range of diseases including cancer, inflammatory disease, infectious disease, metabolic disease, cardiovascular disease and respiratory disease. The nature of Breath Biopsy, and VOC biomarkers, make them perfectly suited to addressing two of the major challenges of healthcare today: early detection and precision medicine.
Breath collection is carried out using Owlstone Medical’s ReCIVA Breath Sampler, which ensures reliable, reproducible collection of VOCs. Subjects breathe a controlled supply of air, and samples of their exhaled breath are captured and stabilized on Breath Biopsy Cartridges, which can then be shipped for analysis with Owlstone Medical’s Breath Biopsy analytical platform, using mass spectrometry or FAIMS to determine their VOC profile. Advanced data analytic techniques can then be applied in order to pinpoint the VOCs of interest.
About Owlstone Medical www.owlstonemedical.com
Owlstone Medical’s vision is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy®. Breath Biopsy operates by detecting volatile organic compounds (VOCs) produced as the end product of metabolic processes within the body or as a result of chemicals from external sources such as diet or medication, changes in which can be characteristic of specific disease or indicate environmental exposure.
The Breath Biopsy platform includes ReCIVA®, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial Breath Biopsy Laboratory located in Cambridge, UK, and the development of the world’s largest Digital Breath Biobank matched to patient phenotype.
Owlstone Medical is deploying the platform to address some of the key challenges of 21st century healthcare. The focus is on the early detection of disease with an emphasis on cancer, with clinical trials underway to develop breath tests for the early detection of lung and colorectal cancer, and on precision medicine through partnerships with large pharmaceutical companies including AstraZeneca and GlaxoSmithKline to enable therapeutics to be deployed more effectively. Owlstone Medical’s technology is currently in use at over 100 sites worldwide.
About Cancer Research UK
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
· Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
· Cancer Research UK receives no funding from the UK government for its life-saving research. Every step it makes towards beating cancer relies on vital donations from the public.
· Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
· Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
· Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
· Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.